Colchicine Safety
Cross-source consensus on Colchicine Safety from 1 sources and 6 claims.
1 sources · 6 claims
How it works
Risks & contraindications
Interactions
Evidence quality
Highlighted claims
- Colchicine is contraindicated in renal or hepatic impairment when taken with P-glycoprotein inhibitors or strong CYP3A4 inhibitors because these drugs can increase colchicine levels. — Colchicine and dialysis patients (CAD): protocol for a feasibility study
- Colchicine is often avoided in dialysis patients because of concerns about accumulation and toxicity in kidney disease. — Colchicine and dialysis patients (CAD): protocol for a feasibility study
- Renal excretion accounts for only 10-20% of total colchicine elimination in people with normal renal function. — Colchicine and dialysis patients (CAD): protocol for a feasibility study
- The protocol states that dialysis-related colchicine toxicity concerns are not based on firm evidence. — Colchicine and dialysis patients (CAD): protocol for a feasibility study
- Many colchicine toxicity reports involved contributing factors such as macrolide antibiotics and calcineurin inhibitors. — Colchicine and dialysis patients (CAD): protocol for a feasibility study
- A non-randomised haemodialysis report found no group differences in myo-neuropathic signs, creatine kinase, myoglobin, or blood counts except higher white blood cell count in the colchicine group. — Colchicine and dialysis patients (CAD): protocol for a feasibility study